Management of Hypertension in Advanced Kidney Disease

Panagiotis I. Georgianos; Rajiv Agarwal

Disclosures

Curr Opin Nephrol Hypertens. 2022;31(4):374-379. 

In This Article

Conclusion

Enablement of more persistent use of spironolactone with the administration of newer agents that bind potassium in the gut, the clinical development of nonsteroidal MRAs with sustained BP-lowering action and a more favourable side-effect profile as well as the recently proven BP-lowering efficacy of the thiazide-like diuretic chlorthalidone are three novel therapeutic opportunities for more effective management of hypertension in advanced CKD. Larger phase 3 clinical trials are clearly warranted to fully elucidate whether these therapeutic strategies can also improve kidney failure and cardiovascular outcomes in this high-risk patient population.

processing....